Damoctocog alfa pegol is a recombinant Factor VIII used to treat hemophilia A to control bleeding, perioperative bleeding, and also for prophylaxis of bleeding. In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval.
- Mechanism
- Curator reviewed · 3 references
This drug is a site-specifically PEGylated recombinant antihemophilic factor, which temporarily replaces the missing coagulation Factor VIII. The site-specific PEGylation in the A3 domain reduces binding to the physiological Factor VIII clearance receptors resulting in a longer half-life and increased AUC (area under the curve).
The active protein, prior to conjugation is a recombinant B-domain deleted human coagulation Factor VIII (BDD-rFVIII) produced by recombinant DNA technology in Baby Hamster Kidney (BHK) cells.
Damoctagol alfa pegol is manufactured by site-specific conjugation of the BDD-rFVIII variant K1804C at the cysteine amino acid position 1804 (within the A3 domain) with a single maleimide-derivatized, 60 kilodalton (kDa) branched PEG (two 30 kDa PEG) moiety. The A3 domain was identified and selected for conjugation to provide both a continual coagulation activity and high PEGylation efficiency.
- Primary indication
- Indicated for use in previously treated adults and adolescents (12 years of age and above) with hemophilia A (congenital Factor VIII deficiency) for: On-demand treatment and control of bleeding episodes, perioperative management of bleeding, and...Curator reviewed · 1 structured indication
- Formula / weight
- 234.0 Da (calculated average molecular weight)
- First approval
- Canada, 2018 · United States, 2018 · European Union, 2021
- Also known as
- Damoctocog alfa-pegol
- Code names
- BAY94-9027
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Damoctocog alfa pegol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account